Despite significant advances in the treatment of multiple myeloma which had led to
unprecedented rates of response and survival, patients still relapse, and cure remains …

The outcomes for the majority of patients with myeloma have improved over recent decades,
driven by treatment advances. However, there is a subset of patients considered to have …

Mutational signature analysis is commonly performed in cancer genomic studies. Here, we
present SigProfilerExtractor, an automated tool for de novo extraction of mutational …

Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need
of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene …

Understanding the profile of oncogene and tumor suppressor gene mutations with their
interactions and impact on the prognosis of multiple myeloma (MM) can improve the …

We performed massively parallel sequencing of paired tumor/normal samples from 203
multiple myeloma (MM) patients and identified significantly mutated genes and copy number …

Multiple myeloma is an incurable plasma cell malignancy with a complex and incompletely
understood molecular pathogenesis. Here we use whole-exome sequencing, copy-number …

Multiple myeloma, a plasma cell malignancy, is the second most common blood cancer.
Despite extensive research, disease heterogeneity is poorly characterized, hampering …

Recent advances in technological tools for massively parallel, high-throughput sequencing
of DNA have enabled the comprehensive characterization of somatic mutations in a large …

We analyzed whole genomes of unique paired samples from smoldering multiple myeloma
(SMM) patients progressing to multiple myeloma (MM). We report that the genomic …